Retrospective Analysis of Patients Treated With Bevacizumab in GHPSJ Intraperitoneal for the Treatment of Refractory Malignant Ascites

2016-09-07 16:23:21 | BioPortfolio


The refractory malignant ascites is a complication of advanced stages of many cancer types. It is characterized clinically by abdominal pressure sensation, shortness of breath and pelvic pain. Thus, it contributes to decreased quality of life for these patients in palliative care.

Conventional treatment is based on paracentesis of ascites. The progression of the disease leads to increased production of ascites requiring more frequent paracentesis. Main therapeutic alternatives are constituted by the controversial use of diuretics and the use of an antibody inhibiting the activity of the Vascular Endothelial Growth Factor (VEGF): bevacizumab. Catumaxomab, a monoclonal antibody anti-EpCAM and CD3, developed for the treatment of refractory malignant ascites showed no sufficient clinical benefit.

VEGF is overexpressed in many tumors. VEGF causes an increase in capillary permeability and capillary filtration surface generating increased protein extravasation. These phenomena are responsible for an increase of the volume of ascites product. Thus the use of inhibitors of VEGF, such as bevacizumab, could reduce the production of ascites.

The efficacy of bevacizumab to decrease the volume of ascites product was demonstrated on small animals in intraperitoneal administration.

Studies in humans are few and the doses used are not consistent from one study to another.


Main objective / secondary:

The objective of this study is to describe the population, adverse effects, the volume of ascites product and time between paracentesis in patients receiving bevacizumab in intraperitoneal through a refractory malignant ascites.

Methodology :

This is a retrospective study mono centric and non-interventional. data collected

- Name,

- date of birth,

- dates and numbers injection of bevacizumab doses

- side effects,

- type of cancer, TNM classification,

- ascites volume collected during paracentesis prior to the introduction of IP bevacizumab,

- frequency of paracentesis before the introduction of IP bevacizumab,

- ascites volume collected during paracentesis after the introduction of IP bevacizumab,

- frequency after paracentesis after the introduction of IP bevacizumab,

- albumin

- Number of lines of chemotherapy received

- Treatment monotherapy or in combination with other chemotherapies

- WHO Stadium in each course

- Date of death


- Data collection from CHIMIO® software DxCare® and non-computerized patient records.

- Series anonymized patient data on Excel®

Circulation mode and data processing and not opposition patient The anonymous data are entered on a computer file and centralized within the pharmacy department by the investigator of the Groupe Hospitalier Saint Joseph Paris, Carole METZ, to be processed locally.

For the statistical analysis, quantitative variables are expressed by their mean, standard deviations, their minimum and maximum values as appropriate. The variables will be expressed in numbers and percentages. Descriptive data analyzes, correlations between the study variables and more specific tests to determine the prognostic value of variable can be used.

This is a single-center retrospective cohort within the GHPSJ. Patients are aware of the potential use of their data in their files for medical research by information contained in the handbook of the institution for patients.

Development of the study:

- The list of patients who received bevacizumab injection is obtained from the CHIMIO® software.

- The data collected is validated by a multidisciplinary way oncologists and pharmacists.

- Collection and analysis of data by the internal pharmacy from computerized patient records (DxCare®) or not computerized.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Refractory Malignant Ascites


No intervention. Descriptive study


Groupe Hospitalier Paris Saint Joseph




Groupe Hospitalier Paris Saint Joseph

Results (where available)

View Results


Published on BioPortfolio: 2016-09-07T16:23:21-0400

Clinical Trials [1748 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites

Malignant ascites is a severe complication of many types of human cancer. Animal and clinical analyses have shown that angiogenesis plays a critical role in the formation of malignant asci...

A Study of Bevacizumab to Prevent Malignant Ascites

The purpose of this study is to determine the effectiveness of using Bevacizumab in the prevention of recurrent malignant ascites. Ascites is a debilitating and unpleasant complication of...

EUS-Guided Drainage of Refractory Malignant Ascites

This study evaluates the efficacy and safety of drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses. Patients with canc...

Trial of Sunitinib for Refractory Malignant Ascites

The study is to see whether treatment with Sunitinib decreases the accumulation of ascites in patients with refractory malignant ascites.

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once daily over 3...

PubMed Articles [15350 Associated PubMed Articles listed on BioPortfolio]

Laparoscopic management of refractory chylous ascites using fluorescence navigation with indocyanine green: A case report.

Postoperative chylous ascites is a rare complication of colorectal surgery. Conservative management is usually effective in most cases of the postoperative chylous ascites. However, surgical intervent...

Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites.

In patients with liver cirrhosis, the clinical benefit of the treatment with human albumin for ascites is debated, and no data are available regarding refractory ascites. In this study, in patients wi...

Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.

The study aimed to evaluate the effects of tolvaptan treatment on survival of patients with decompensated liver cirrhosis with refractory ascites.

Refractory Hepatic Hydrothorax in the Absence of Ascites as a First Sign of Cirrhosis.

Hepatic hydrothorax (HH) occurs in 5-10 percent of patients with cirrhosis and usually develops in conjunction with ascites. We report a case of refractory right sided pleural effusion which turned ou...

Permanent peritoneal ports for the management of recurrent malignant ascites: a retrospective review of safety and efficacy.

Large volume paracentesis is effective in relieving the symptoms of malignant ascites, but frequent procedures are often required. Permanent peritoneal ports are an alternative to repeated procedures....

Medical and Biotech [MESH] Definitions

A study in which observations are made before and after an intervention, both in a group that receives the intervention and in a control group that does not.

A study that uses observations at multiple time points before and after an intervention (the "interruption"), in an attempt to detect whether the intervention has had an effect significantly greater than any underlying trend over time.

A study that compares a group of participants receiving an intervention with a similar group from the past who did not.

Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.

The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.

More From BioPortfolio on "Retrospective Analysis of Patients Treated With Bevacizumab in GHPSJ Intraperitoneal for the Treatment of Refractory Malignant Ascites"

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...

Searches Linking to this Trial